Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5299]

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer compared to sorafenib

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer...

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to chemotherapy alone

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to...

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC previously treated with sorafenib

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC...

Combination therapies may improve outcomes due to independent, rather than synergistic or additive, drug action

Combination therapies may improve outcomes due to independent, rather than synergistic or additive, drug action

Magnesium is essential for the immune system, including in the fight against cancer

Magnesium is essential for the immune system, including in the fight against cancer

New treatment target ID’d for radiation-resistant cervical cancer

New treatment target ID’d for radiation-resistant cervical cancer

First-in-human trial with CAR macrophages shows the cell therapy may be safe, feasible for solid tumours

First-in-human trial with CAR macrophages shows the cell therapy may be safe, feasible for solid tumours

Identification of a novel therapeutic target in multiple myeloma

Identification of a novel therapeutic target in multiple myeloma

Journeys - a photo essay

Journeys - a photo essay

Researchers identifies new drug combo for liver cancer via CRISPR-Cas9 screen

Researchers identifies new drug combo for liver cancer via CRISPR-Cas9 screen

More from ecancer